Co-Diagnostics Q2 2022 revenue $5.0M, down 82% YoY; net loss $2.7M

Co-Diagnostics, Inc.

2022-Q2 EPS reported $0.27 revenue$27,722,270

Revenue of $5.0M vs $27.4M a year ago; gross profit margin 81.8% due to sales volume inefficiencies.
Net loss of $2.7M ($0.08 loss per diluted share) compared to net income of $9.8M in Q2 2021.
Operating loss of $4.1M vs operating income of $11.8M; adjusted EBITDA loss $2.3M.
Cash, equivalents, and marketable securities at $96.0M as of June 30, 2022.
Business highlights: Indian JV CoSara cleared for Hepatitis C test; monkeypox test reagents shipped; Co-Dx PCR Home platform optimization continues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.